Literature DB >> 15830011

Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis.

P Dreger1, R Brand, D Milligan, P Corradini, J Finke, G Lambertenghi Deliliers, R Martino, N Russell, A van Biezen, M Michallet, D Niederwieser.   

Abstract

To elucidate whether reduced-intensity conditioning (RIC) decreases treatment-related mortality (TRM) after allogeneic stem cell transplantation (allo-SCT) for chronic lymphocytic leukemia (CLL), we retrospectively compared 73 RIC cases from a recent EBMT survey with 82 patients from the EBMT database who had undergone standard myeloablative conditioning (MC) for CLL during the same time period. The two populations were matched by adjusting the primary risk factor, the conditioning regimen, in a series of Cox models for age, sex, donor type, remission status at transplant and analyzed for its effect on TRM, relapse incidence, event-free (EFS) and overall survival (OS). After adjustment, a significant reduction of TRM became evident for the RIC population (hazard ratio (HR) 0.4 (95% confidence interval 0.18-0.9); P=0.03). On the other hand, RIC was associated with an increased relapse incidence (HR 2.65 (0.98-7.12); P=0.054). There was no significant difference between RIC and MC in terms of EFS (HR 0.69 (0.38-1.25); P=0.22) and OS (HR 0.65 (0.33-1.28); P=0.21). We conclude that RIC appears to favorably influence TRM after allo-SCT for CLL. This observation, as well as possible detrimental effects of RIC on relapse risk, should be confirmed by prospective studies.

Entities:  

Mesh:

Year:  2005        PMID: 15830011     DOI: 10.1038/sj.leu.2403745

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  36 in total

1.  Post-transcriptional silencing of Notch2 mRNA in chronic lymphocytic [corrected] leukemic cells of B-CLL patients.

Authors:  Kaneez Fatima; Rehan Zafar Paracha; Ishtiaq Qadri
Journal:  Mol Biol Rep       Date:  2011-12-10       Impact factor: 2.316

Review 2.  Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia.

Authors:  John G Gribben; Chitra Hosing; David G Maloney
Journal:  Biol Blood Marrow Transplant       Date:  2011-01       Impact factor: 5.742

3.  Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning.

Authors:  Parameswaran Hari; Jeanette Carreras; Mei-Jie Zhang; Robert Peter Gale; Brian J Bolwell; Christopher N Bredeson; Linda J Burns; Mitchell S Cairo; César O Freytes; Steven C Goldstein; Gregory A Hale; David J Inwards; Charles F Lemaistre; Dipnarine Maharaj; David I Marks; Harry C Schouten; Shimon Slavin; Julie M Vose; Hillard M Lazarus; Koen van Besien
Journal:  Biol Blood Marrow Transplant       Date:  2008-02       Impact factor: 5.742

4.  Achievement of complete remission of refractory hairy cell leukemia by rituximab progressing after allogeneic hematopoietic stem cell transplantation.

Authors:  Junichi Kiyasu; Motoaki Shiratsuchi; Rie Ohtsuka; Eriko Sada; Kensaku Idutsu; Eriko Nagasawa; Ryoichi Takayanagi; Yasunobu Abe
Journal:  Int J Hematol       Date:  2009-03-31       Impact factor: 2.490

Review 5.  Therapy of chronic lymphocytic leukaemia with purine nucleoside analogues: facts and controversies.

Authors:  Tadeusz Robak
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

6.  Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.

Authors:  Tetsuya Nishida; Michael Hudecek; Ana Kostic; Marie Bleakley; Edus H Warren; David Maloney; Rainer Storb; Stanley R Riddell
Journal:  Clin Cancer Res       Date:  2009-06-30       Impact factor: 12.531

7.  Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.

Authors:  Uri Rozovski; Ohad Benjamini; Preetesh Jain; Philip A Thompson; William G Wierda; Susan O'Brien; Jan A Burger; Alessandra Ferrajoli; Stefan Faderl; Elizabeth Shpall; Chitra Hosing; Issa F Khouri; Richard Champlin; Michael J Keating; Zeev Estrov
Journal:  J Clin Oncol       Date:  2015-04-06       Impact factor: 44.544

Review 8.  Stem cell transplantation in chronic lymphocytic leukemia.

Authors:  John G Gribben
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

9.  Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Authors:  Alice Garnier; Marie Robin; Fabrice Larosa; Jean-Louis Golmard; Steven Le Gouill; Valérie Coiteux; Reza Tabrizi; Claude-Eric Bulabois; Victoria Cacheux; Mathieu Kuentz; Brigitte Dreyfus; Peter Dreger; Bernard Rio; Marie-Pierre Moles-Moreau; Karin Bilger; Jacques-Olivier Bay; Véronique Leblond; Didier Blaise; Olivier Tournilhac; Nathalie Dhédin
Journal:  Haematologica       Date:  2010-01-15       Impact factor: 9.941

Review 10.  Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation.

Authors:  Masahiro Imamura; Junji Tanaka
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.